No Data
No Data
Express News | Eloxx Pharmaceuticals Inc: Signed Global Licensing Partnership for Zkn-013 With Almirall Pharmaceuticals With $3M Upfront and up to $470M in Milestones
Express News | Eloxx Pharmaceuticals Inc: Elx-02 Granted Orphan Drug Designation (Odd) From U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Express News | Eloxx Pharmaceuticals Provides Elx-02 and Zkn-013 Program Updates
Alport Syndrome Pipeline Insight 2024, Featuring Eloxx Pharmaceuticals, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics and Reata Pharmaceuticals
Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
Almirall and Eloxx Pharmaceuticals Enter Into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I read
No Data
W poplar : Innumerable